Ablation-Index Guided Ventricular Tachycardia Ablations
Launched by RUSH UNIVERSITY MEDICAL CENTER · Sep 18, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new approach to treat a heart condition called ventricular tachycardia (VT), which is a type of abnormal heart rhythm that can be serious. The researchers want to see if using a method called the Ablation Index (AI) can help doctors create better and more effective treatments for patients with structural heart disease, particularly those who have had a heart attack or other heart issues. The trial will involve patients who are at least 18 years old and have a specific type of VT that can be seen through an ECG (a test that measures electrical activity in the heart).
If you or a family member are considering participating in this trial, it's important to know that you must meet certain criteria. For example, you should have a history of heart disease and have experienced sustained VT. However, if you have had other types of arrhythmias or recent heart surgery or stroke, you may not be eligible. Participants in this study will help researchers gather information about how well this AI-guided treatment works and its safety, contributing to better heart care for people in the future. The trial is not yet recruiting participants, so keep an eye out for updates if you're interested!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient ≥ 18 y.o.
- • Structural Heart Disease: Ischemic Cardiomyopathy
- • Sustained Scar-related Monomorphic Ventricular Tachycardia documented by ECG or CIED interrogation
- Exclusion Criteria:
- • If clinical ventricular arrhythmia is predominantly PVCs, polymorphic ventricular tachycardia, or ventricular fibrillation
- • Myocardial infarction or Cardiac Surgery within 6 months
- • Severe mitral regurgitation
- • Stroke or TIA within 6 months
- • Prior Ventricular Tachycardia Ablation
About Rush University Medical Center
Rush University Medical Center is a leading academic medical institution located in Chicago, Illinois, dedicated to advancing healthcare through innovative research and clinical trials. As a sponsor of numerous clinical studies, Rush focuses on translating scientific discoveries into effective treatments and improving patient outcomes across a variety of medical disciplines. With a commitment to excellence in patient care, education, and research, Rush leverages its state-of-the-art facilities and a robust network of specialists to conduct comprehensive trials that adhere to the highest ethical and regulatory standards. Through collaboration with a diverse patient population, Rush aims to enhance the understanding of diseases and develop novel therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Charleston, South Carolina, United States
Chicago, Illinois, United States
Cleveland, Ohio, United States
Ann Arbor, Michigan, United States
Patients applied
Trial Officials
Henry D Huang, MD
Principal Investigator
Rush University Medical Center
Jackson Liang, DO
Study Chair
University of Michigan
Jeffrey Winterfield, MD
Study Chair
The Medical University of South Carolina
Pasquale Santangeli, MD, PhD
Study Chair
The Cleveland Clinic
Jeanne M du Fay de Lavallaz, MD-PhD
Study Chair
Rush University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported